In recent months, Haemonetics has reported a recovery in its Hospital division, supported by broader adoption of its FDA-approved NexSys PCS system with Persona Technology and the completed transition ...
Haemonetics HAE has been benefiting from business growth within Plasma, Hospital and Hemostasis Management. New launches are also aiding growth. The stock carries a Zacks Rank #1 (Strong Buy).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results